Iskra Reic

NeoPhore

Michael Shih

NeoPhore has appointed Michael Shih as chief executive officer. Shih, who has also been appointed to the company’s board of directors, takes on the role after serving as vice president of corporate development at Kite Pharma. He was also previously senior vice president, head of business development at Biogen, and vice president and head of global transactions at Sanofi.

Bausch Health

Jonathan Sadeh

Bausch Health has appointed Jonathan Sadeh as executive vice president, chief medical officer and head of research and development. Sadeh most recently served as senior vice president and global programmes head for immunology, cardiovascular and neuroscience at Bristol Myers Squibb, and previously held key positions at Sanofi, AstraZeneca and Schering-Plough.

IFPMA

Thomas Schinecker

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) has appointed Thomas Schinecker as president. Schinecker, who most recently served as chief executive officer of Roche Group, brings extensive experience to the role. He joined Roche over two decades ago and more recently served as chief executive officer of Roche Diagnostics and Roche Pharma.

Theolytics

David Apelian

Theolytics has appointed David Apelian as chief executive officer. Apelian has 25 years of leadership experience and was recently the founding chief executive officer of BlueSphere Bio. Previously, he served as chief medical officer of Achillion Pharmaceuticals and GlobeImmune, and held positions at Bristol Myers Squibb and Schering Plough earlier in his career.

Klotho Neurosciences

Riad El-Dada

Klotho Neurosciences has appointed Riad El-Dada to its board of directors. El-Dada brings extensive experience in product development, commercialisation and strategic partnerships to the role, having recently served as US President of Merck. He was also previously managing director for the company’s Australian and New Zealand operations.

Sanofi

Jean-Paul Kress

Sanofi has appointed Jean-Paul Kress as an independent director. Kress joins the board with significant industry experience, having previously served as chief executive officer of MorphoSys and Syntimmune. Kress was also previously executive vice president, president international and head of global therapeutic operations at Biogen.

Marea Therapeutics

Max Zeiberg

Marea Therapeutics has appointed Max Zeiberg as senior vice president, corporate development. Zeiberg brings significant industry experience to the role, having served as vice president, business development at both Sana Biotechnology and Graphite Bio. Prior to this, he held roles of increasing responsibility on the corporate development team at Gilead Sciences.

Marea Therapeutics

Rebecca Juliano

Marea Therapeutics has appointed Rebecca Juliano as chief development officer. Juliano has been in lipid-related research for more than 25 years and most recently served as chief operating officer at a Stealth Biotech startup. Prior to this, she led the clinical and related teams at Amarin Pharma and held roles at Reliant Pharmaceuticals.